BC Extra | Oct 19, 2019
Company News

CHMP backs Merck’s Ebola vaccine, a first

EMA’s CHMP issued its first positive opinion for an Ebola vaccine and backed AbbVie’s rheumatoid arthritis treatment. The agency recommended approving Ervebo (rVSV-ZEBOV) from Merck & Co. Inc. (NYSE:MRK), to prevent infection by the Ebola...
BC Extra | Aug 16, 2019
Company News

Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday...
BC Innovations | Jun 19, 2019
Distillery Therapeutics

Agonizing TrkB to restore cognitive function after chemotherapy

DISEASE CATEGORY: Neurology INDICATION: Cognitive dysfunction Agonizing TrkB in patients treated with methotrexate chemotherapy could induce myelination and treat chemotherapy-induced cognitive impairment. Methotrexate exposure blocks activity-related myelination, which supports adaptive neurological function. In mice that...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Extra | Mar 28, 2019
Clinical News

Filgotinib hits more RA endpoints

Gilead and Galapagos took a step closer to submitting regulatory applications for filgotinib to treat rheumatoid arthritis after the partners reported positive data from the two remaining Phase III trials of the oral Janus kinase-1...
BC Week In Review | Jan 18, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Extra | Jan 17, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Innovations | Dec 12, 2018
Distillery Therapeutics

Neurology

INDICATION: Neurology Patient sample and mouse studies suggest depleting microglia with CSF1R inhibitors could help treat chemotherapy-induced neurological dysfunction. In postmortem frontal lobe tissue samples from pediatric and young adult patients treated with methotrexate and...
BC Week In Review | Oct 26, 2018
Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to...
BC Extra | Oct 22, 2018
Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to...
Items per page:
1 - 10 of 1087